These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34597287)

  • 1. Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab.
    Tursi A; Florio T; Tiano M
    Eur J Gastroenterol Hepatol; 2021 Nov; 33(11):1462-1464. PubMed ID: 34597287
    [No Abstract]   [Full Text] [Related]  

  • 2. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab (Skyrizi) - An IL-23 antagonist for Crohn's disease.
    Med Lett Drugs Ther; 2022 Dec; 64(1666):153-157. PubMed ID: 36542348
    [No Abstract]   [Full Text] [Related]  

  • 4. Risankizumab: First Global Approval.
    McKeage K; Duggan S
    Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risankizumab for Crohn's disease.
    Hibi T
    Lancet; 2022 May; 399(10340):1992-1993. PubMed ID: 35644143
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease.
    Umeno J; Matsumoto T; Jo Y; Ichikawa M; Urabe K; Iida M
    Inflamm Bowel Dis; 2007 Sep; 13(9):1188-9. PubMed ID: 17427237
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
    Ferrante M; Feagan BG; Panés J; Baert F; Louis E; Dewit O; Kaser A; Duan WR; Pang Y; Lee WJ; Gustafson D; Liao X; Wallace K; Kalabic J; D'Haens GR
    J Crohns Colitis; 2021 Dec; 15(12):2001-2010. PubMed ID: 34077509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risankizumab for Induction and Maintenance of Remission in Crohn's Disease.
    Khanna R
    Gastroenterology; 2022 Nov; 163(5):1470-1471. PubMed ID: 35961380
    [No Abstract]   [Full Text] [Related]  

  • 10. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risankizumab in patients with Crohn's disease].
    Blumenstein I; Nitschmann S
    Inn Med (Heidelb); 2023 Jan; 64(1):102-106. PubMed ID: 36515721
    [No Abstract]   [Full Text] [Related]  

  • 12. [A case of psoriasis induced by infliximab treatment for Crohn's disease].
    Jwa YJ; Kim NH; Park HJ; Park JS; Bae WK; Kim KA; Lee JS; Moon YS
    Korean J Gastroenterol; 2010 Nov; 56(5):324-8. PubMed ID: 21099241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
    Deepak P; Sandborn WJ
    Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.
    van den Reek JM; Pijls PA; Tummers M; van Riel PC; Kievit W; Hoentjen F; de Jong EM
    J Am Acad Dermatol; 2016 Jan; 74(1):177-9. PubMed ID: 26702800
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis.
    Bissonnette R; Tamaz R; Bolduc C; Maari C; Robillard C; Nigen S; Delorme I; Lynde C
    J Am Acad Dermatol; 2017 Oct; 77(4):755-756. PubMed ID: 28917455
    [No Abstract]   [Full Text] [Related]  

  • 18. Guttate psoriasis induced by infliximab in a child with Crohn's disease.
    Costa-Romero M; Coto-Segura P; Suarez-Saavedra S; Ramos-Polo E; Santos-Juanes J
    Inflamm Bowel Dis; 2008 Oct; 14(10):1462-3. PubMed ID: 18383177
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
    Visvanathan S; Baum P; Salas A; Vinisko R; Schmid R; Grebe KM; Davis JW; Wallace K; Böcher WO; Padula SJ; Fine JS; Panés J
    J Crohns Colitis; 2018 Nov; 12(10):1170-1179. PubMed ID: 30032288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab.
    Grossberg LB
    Inflamm Bowel Dis; 2019 Jun; 25(7):e84. PubMed ID: 30863855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.